Sg3 Management, LLC Neurocrine Biosciences Inc Transaction History

Sg3 Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $732,530 - $841,755	-8,500 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $1.48 Million - $1.69 Million	-16,500 Reduced 66.0%	8,500 $827,000
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $1.58 Million - $2.15 Million	18,000 Added 257.14%	25,000 $2.43 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $480,800 - $675,750	5,000 Added 250.0%	7,000 $673,000
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $170,180 - $260,720	2,000 New	2,000 $244,000

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.